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Blood  and  the  products  derived  from  it  have  become  an  indispensable  facet  of modem 
medicine.  Their use has  brought  about  dramatic  advances  in  therapy  and  surgery,  saved 
countless lives, and improved significantly the longevity as well as the quality of  life for those 
who suffer from long-term blood disorders such as haemophilia. Ensuring the safety and the 
supply of blood and blood products, therefore, is of vital importance - safeguards which are 
directly  related  to  the  public  health  objectives  of Articles  J(o)  and  129  of the  Treaty 
establishing the European Community. These objectives, which focus on health protection and 
disease prevention, are particularly important considerations in the context ofHIV/AIDS and 
certain  other communicable diseases which can be spread  through the provision of unsafe 
blood and blood products. 
An  essential  requisite  for  health  protection  is  the  prevention  of diseases,  which  entails 
minimizing exposure to risk factors implicated in their causation. It was bearing this in mind 
that the Council  adopted Directive 89/381/EEC
1 related  to  medicinal  products derived  f.-om 
human  blood and plasma in order to ensure a high level  of protection of public health.  In 
addition to introducing strict manufacturing criteria, the Directive required Member States to 
take the necessary measures to prevent the transmission of  infectious diseases and to promote 
Community self-sufficiency in human blood and plasma through voluntary unpaid donations. 
A repotr to the Council on the state of Community  self-sufficiency resulted in it adopting 
Conclusions
3  in which the need to achieve this goal  through  cooperation between Member 
States  was  reaffirmed  and  the  continued  promotion  of the  quality  and  safety  of blood 
collection and blood-derivative production was inter alta agreed. 
The Council's continuing eoncern about the quality.  safety.  and  efficacy of blood and blood 
products resulted in it requesting,  at its meeting of 13  December 1993, the Commission to 
prepare a repon related to the legal provisions and current practices in the Member States on 
the collection,  control,  and  treatment of blood  and the  distribution and trade in  blood and 
blood produets with a view to proposing common safety criteria.  Immediately following this 
meeting,  the  Commission  invited  Member·  States  to  provide  their  legal  regulations  and 
administrative provisions in this area. 
This  Communication draws upon  the  responses provided by  the Member States in  written 
submissions and during meetings of experts on self-sufficiency and blood safety convened by 
the Commission. It addresses issues raised by  the Ministers for Health,  and provides,  as  a 
background, a review of progress towards blood self-sufficiency in the Community as  well  as 
coverage of this area by existing Community rules and  regulations. Finally, it specifies the 
need for Community action in this area particularly in the context of the Council's Resolution 
concerning  the field  of public health"'  and  the  Commission Communication on  AIDS  and 
certain other communicable diseasess.  · 
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2.  BLOOD AND  ITS SIGNIFICANCE FOR PUBLIC HEALTH 
As a consequence of significant scientific and technical advances both with regard to medical 
knowledge and surgical techniques, blood has come to be regarded as a major cornerstone of 
modem day medicine contributing significantly not only to saving but to improving the lives 
of  many. Blood also has particular significance since in spite of  its therapeutic uses, it can also 
be a purveyor of disease. 
2.1  Blood as a therapeutic substance 
Since early  in  the twentieth century,  blood  transfusion  has  increased in  importance in  the 
practice  of medicine  saving  millions  of lives  throughout  the  world.  With  advances  in 
technology and breakthroughs in research and development, however, the use of whole blood 
in transfusion medicine has progressively diminished with its individual components assuming 
major therapeutic importance. As outlined in the Commission's Staff Working Paper
6 and its 
Communication on blood self-sufficiency, blood is comprised of almost equal portions of the 
cellular components  -red blood cells, white blood cells and platelets- and the clear yellowish 
fluid  portion called plasma.  Plasma can be separated from the cellular components through 
centrifugation or obtained by plasmapheresis (the process of  removing whole blood, separating 
the red cells from the plasma and returning them to the donor), stored as fresh frozen plasma 
(FFP)  and  then,  after thawing,  transfused  into a patient.  It can  also be fractionated  into a 
number of stable  industrially  prepared  derivatives  - albumin,  clotting  factor  concentrates, 
protease inhibitors and immunoglobulins. 
The extent to which these blood products are used in medicine or surgery (Annex  1)  ranges 
from the administration of red blood cell concentrates due to thalassemia; to albumin in cases 
of shock; to the use of immunoglobulins to. prevent a variety of infectious diseases such as 
hepatitis, chicken pox, tetanus, and rabies; to regular and life-long treatment of haemophilia 
patients with clotting factor concentrates. Moreover, stem cells are being used increasingly for 
bone marrow transplantation. 
2.2  Blood as  a transmitter of diseases 
In spite of notable therapeutic advances, blood continues to be one of several media by which 
diseases may be transmitted, as the tragic consequences surrounding the administration of  HIV 
(human immunodeficiency virus) contaminated blood and blood products have made all  too 
clear.  Although  HIV  has  attracted  the  attention  of clinicians,  governmental  authorities, 
politicians, patients and the lay public, numerous other agents that are transmissible by blood 
·do exist. Of the five main types of infectious agents- viruses, bacteria, spirochetes, parasites 
and fungi - transmission of the first four by  blood transfusion has been reported (Annex 2). 
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As  viral  infections can be  transmitted by  virus-infected blood cells or by  the free  virus  in 
plasma,  the  virus-types transmissible by  the cellular components and  plasma  differ.  Viral 
infections transmissible by  whole blood and  blood cell  concentrates (notably  red  cells and 
platelets) include the human immunodeficiency viruses, the hepatitis viruses, parvovirus B 19, 
the human T  -cell  leukaemia viruSes,  cytomegalovirus and the Epstein B~  virus.  The first 
three can also be transmitted by whole plasma and plasma derivatives. 
Infection  with  these  different  viruses  may  lead  to  various  diseases  such  as  severe 
immunodeficiency from mv and cirrhosis from the hepatitis viruses. 
Several non-viral organisms transmissible by blood transfusion, such as spirochetes, parasites 
and  bacteria  can  be  the  cause  of infections,  and  blood  from  donations  can  become 
contaminated by bacteria (e.g.  staphylococci) at the time of donation. 
2.3  Blood as a Commodity 
There are mixed emotions surrounding the use of blood as  a commodity.  On the one hand, 
there is strong sentiment that the human body and its parts are inviolable and that no profit 
or commercialization should be derived from them; on the other hand, there is an increasing 
demand for blood products, including high purity plasma derivatives that have been developed 
as a result of continuing research and development and  at considerable expense.  In  spite of 
the altruistic and  unpaid nature of many blood and plasma donations, however, the costs of 
the collection, testing,  processing,  handling,  storage and  distribution associated  with  blood 
products are high and have to be met in one way or another. 
Trade in blood and blood products,  therefore,  has to be considered from  the perspective of 
whole blood and  its cellular components,  on the one hand,  and that of medicinal  products 
derived from  plasma on the other. 
2.4  The blood transfusion chain 
The numerous activities that occur from the moment an individual offers to donate blood or 
plasma until after the blood product has been administered to the patient can be described as 
the blood transfusion chain.  The first link in this chain is the donor whose state of health is 
important not only for him/herself but for the recipient at the end of the chain. The second 
major link is the testing of the donation itself for any  indication of a disease that could be 
potentially transmitted, removal and destruction of  any donation that is infected, and medical 
consultation with those donors who are suspected of  having a communicable disease. The third 
major link is viral inactivation of the medicinal products derived from plasma in accordance 
with  agreed  good  manufacturing  practices.  The fourth  crucial  link  is  the appropriate and 
prudent administration of the blood product to the patient by the treating physician.  And the 
final  link is the  follow-up  of patients who  have  received  any  blood  product in  case they 
develop an immune reaction or other adverse side-effect. 
By ensuring that the risks associated with each link are minimized, the overall safety of the 
blood transfusion chain thus can be assured. 4 
2.5  Precautionary measures regarding blood safety 
As  blood and plasma are biological substances, there is always the danger that they will be 
contaminated  by  infectious  agents.  The  risk  of a  disease  occuring  as  a  result  of their 
transmission by blood and plasma varies depending on their prevalence in the population; the 
state of health of  the donor who may have a natural immunity to certain viruses; the immunity 
of recipients  who  may  have  antibodies  that  neutralize  certain  infectious  agents;  and  the 
quantity of the infectious agent in the blood or plasma donation. 
To ensure the highest level of blood safety,  three key  elements need to be addressed  - the 
selection of donors, the testing of donations,  and the removal  or inactivation of infectious 
agents. As donor selection is directed towards guaranteeing not only the safety of  the recipient 
but also the health of the donor, questions that may identify factors linked to possible disease 
transmission or hazardous to the donor's own health, such as drug use,  presence of diseases, 
recent  surgery  or child  birth,  or visits  to  endemic areas,  need  to be posed.  In  addition, 
examination of  key physical parameters, such as blood pressure and haemoglobin level, needs 
to  be carried out.  Based on defined criteria,  donors can then be accepted,  deferred or not 
accepted for donation.  In some such cases,  medical  treatment may be required.  Awareness 
among donors themselves of the dangers of disease transmission by blood may also result in 
voluntary self-exclusion. 
Testing blood donations takes into account blood group detennination on the one hand and 
the identification of  infectious agents on the other. Screening for viral infections transmissible 
by blood is carried out by the detection of  specific antibodies or antigens (infectious markers) 
against the agent concerned. Specialized procedures, however, are required to identify bacteria 
and parasites. Donations found to be positiv~ for infection should be discarded and the donor 
concerned  should be invited to be retested,  using confirmatory tests,  which  may  result  in 
deferment of further donations.  -
Efforts to deveJ·op  safe and effective methods of removing bacteria and viruses from  whole 
blood and its cellular components, without changing their integrity, continue.  Donor selection 
and the screening of individual donations as well  as proper processing and storage of these 
components are key elements in these efforts. 
For manufactured medicinal products derived from plasma, viral inactivation procedures exist 
thus minimizing the risk of  viral transmission. Techniques for virally inactivating fresh frozen 
plasma are currently clinically validated. 
The on-going efforts of those concerned with the safety of blood and blood products have 
helped to reassure donors and patients that all  possible measures are being taken to protect 
their health.  Nevertheless, in order to ensure the delivery of safe blood and blood products 
there is a need to be ever vigilant to the prevalence of infectious markers, which differ from 
area to area. to the appearance of as yet uoknown pathogens, as well as to the appearance of 
new variants of existing viruses. s 
3.  ACTIVITIES  UNDERTAKEN  AT  COMMUNITY  LEVEL  REGARDING 
BLOOD SAFE1Y 
Within  the European  Community,  specific  measures  have  been  taken  and  calls for  further 
action have been made to ensure the safety of the blood supply as well as to protect the health 
of both the donor and the recipient. 
3.1  CouncU 
The free movement of industrially manufactured medicines, taking as a base a high level  of 
health protection,  has been the primary objective of Community pharmaceutical  legislation. 
Its provisions include directives, guidelines for quality, safety and efficacy studies, marketing 
authorization procedures and requirements with  regard to good manufacturing practice.  As 
outlined in the Communication on blood self-sufficiency, recognition that existing provisions 
were inadequate with regard to proprietary medicinal products derived from  human blood or 
human plasma led to the adoption of Directive 89/381/EEC, which includes reference to the 
goal  of  self-sufficiency,  as  well  as  requirements  for  good  manufacturing  practice 
(91/356/EEC
7
)  and testing (91/507/EEC
1
). In addition, an early information exchange system 
on defective medicinal products was set up under Directive 75/319/EEC' in an effort to keep 
all competent authorities informed of problems that could result in the withdrawal of  or major 
changes to the marketing authorization of a given product. 
The  COuncil's  Conclusions  (94/C 15/03
1
') on  self-sufficiency  in  blood  in  the  European 
Community reaffirmed the need to achieve this goal through cooperation between the Member 
States and agreed inter alia to continue to promote the quality and safety of blood collection 
and of blood-derivative production. 
With regard to the exclwige of blood and its components in cases of emergency, the Council 
adopted  Decision  86/346/EEC
11  accepting.  on  behalf  of the  Community,  the  European 
Agreement on the Exchange of Therapeutic Substances of Human Origin. 
Council Decision 91/317/EEC
12 adopting the 1991-1993  "Europe Against AIDS programme" 
specifically identified, in the plan of action, the prevention of mv  transmission through the 
fostering of Community self-sufficiency in blood products by encouraging voluntary unpaid 
donors  and  continuing  the  efforts  made  to  ensure  trmsfusion  safety.  Council  Resolution 
94/C 15/02
13 called for the extension of  this plan of  action until the end of 1994~ following the 
Commission's proposals, the European Parliament md the Council are set to adopt a Decision 
under Article 129 prolonging the programme until the end of 1995. 
With  regard to the framework for Community  action  in the field  of public health, Council 
Resolution 94/C165/0ll
4  agreed  that priority  should be given inter alia to AIDS  and  other 
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communicable  diseases  as  well  as  disease  surveillance  and  the  collection  of reliable  and 
comparable health data. It emphasized that Community action should be aimed at supporting 
and  encouraging cooperation between Member States  and  promoting coordination of their 
policies and  programmes for health protection in the priority areas. 
Recognizing the risks of the spread of communicable diseases within the Community due to 
the existence of the single market and the free movement of persons and foodstuffs, Council 
adopted  Resolution  92/C326/0 1
15  on  the  monitoring  and  surveilhuice  of communicable 
diseases.  In  its  Conclusions  94/CIS/04
16  on  this  matter,  Council  stressed  the  need  for  an 
epidemiological  network  in  the  Community,  covering  all  diseases  but  collecting  data  on 
communicable diseases as a priority with a view to acquiring better knowledge of  their causes 
and their epidemiological context. 
3.2  European Parliament 
The concern of the European Parliament about the safety of blood and its derivatives and its 
support for the goal of Community self-sufficiency has been reflected in a report
17
,  numerous 
written and oral questions dealing with blood-related issues, as well as in the adoption of  two 
Resolutions
11
'
19 which called inter alia, for an action plan to improve safety and promote self-
sufficiency through voluntary unpaid donations, for the strengthening of controls to increase 
blood  and  blood  product  safety,  and  for  the  drawing  up  of an  instrument  which  would 
guarantee monitoring of blood safety from  donation to use.  It also called on the Council to 
promote in-depth discussions on  these issues and the setting up  of a European blood safety 
authority. 
Parliament has  also taken  considerable  interest  in  the frequency  and  incidence of various 
communicable  infectious  diseases.  It  has  adopted  resolutions  concerning  the fight  against 
AIDS which reflect its concern about the spread of  the epidemic and the need for Community 
intervention. Parliament also expressed the need for epidemiological surveillance, analysis, and 
training  in  its  resolution  on  public  health  policy  after Maastricht
20
,  which  called  on  the 
Commission  to  set  up  an  epidemiological  investigation  service,  to  collect,  arialyse  and 
disseminate  data  on  notifiable  diseases  and  to  encourage the  setting-up  and  operation  of 
exchange schemes for health professionals. 
3.3  European Commission 
The Commission's Communication on self-sufficiency in blood and plasma in the Community 
presented  inter  alia  key  issues  of concern  to  Member  States  and  specific  actions  for 
consideration. Its acceptance led to a request for additional information related to legal  and 
trade  aspects  of the  blood  transfusion  chain  with  the  view  to  proposing  common  safety 
criteria. 
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Regarding the safety and reliability of in vitro diagnostic medical  devices, the Commission 
is  preparing a  proposal  for  a Directive laying down,  in  the context of blood  transfusion, 
essential  requirements to  enhance  health  protection and  safety  of patients, users  and  third 
persons.  It contains provisions covering reagents and equipment specifically intended for in 
vitro  examination of blood (e.g.  blood groups; mv and  hepatitis tests)  which will  be the 
subject of strict conformity assessment procedures implying the intervention of third party 
certification bodies. 
Additional safety precautions related to plasma pool testing and batch release for medicinal 
products derived from blood have been introduced by the Committee for Proprietary Medicinal 
Products (CPMP) in which the competent authorities of the Member States are represented. 
Furthennore,  tests  to  be carried  out on  samples  of each  production  batch  by  an  official 
laboratory prior to being placed on the market, should this be requested by a Member State, 
have been defined. 
The Commission has  prepared sevetal Communications which address aspects relevant to the 
promotion of  blood safety and self-sufficiency including: the implementation of  the 1991-1993 
"Europe Against AIDS"  programme
21 ~ the framework for action in the field of  public health
22
; 
the action programme related to health promotion, information, education and training
23
;  and 
an action programme on the prevention .of AIDS and certain other communicable diseases. It 
has also received the advice of its Group of Advisers on the Ethics of Biotechnology. 
4.  COMMUNITY  SELF-SUFFICIENCY  AND  CONDIDONS  FOR  ITS 
ATTAINMENT 
One of the measures that have been identified as helping to promote the safety of blood and 
its products has been the attainment of self-sufficiency through voluntary non-remunerated 
donations. Promoted by the Council of Europe and supported by the Community, it is based 
on the fundamental  principle that the human body and its parts are inviolable and should not 
be used for the purposes  of trade.  Protecting the health of the donor and  avoiding donor 
exploitation~ minimizing the risk of infection to recipients~ ensuring donor participation from 
all social strata of  the population irrespective of  economic status; and promoting independence 
from importation and hence stability in the supply and cost of products have been presented 
as complementary tenets to this principle. 
In adopting Directive 89/381/EEC, which covers blood and plasma as the starting material for 
the  preparation  of medicinal  products,  Council  accepted  Community  self-sufficiency  (as 
distinct from national self-sufficiency) through voluntary unpaid blood and plasma donations 
as a goal. Its attainment, however, is influenced by several factors: the willingness of the citi-
zens of the Member States to donate blood  and  plasma~ the interpretation in the Member 
States of non-remunerated donations as defined by the Council of  Europe~ optimal use of  these 
products by  treating  physicians  taking  fully  into  account  the very  special  nature of their 
21 
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source;  and  differing  regulations  and  practices  in  the  Community  which  may  restrict  the 
exchange of blood and blood products between Member States and hinder the attainment of 
self-sufficiency. Safety aspects of the blood transfusion chain, irrespective of the end use of 
the blood and plasma donation, also need to be considered particularly in  relation to whole 
blood,  plasma  and  blood  cells  of human  origin,  which  were  specifically  excluded  from 
Directive 89/381/EEC and to which its requirements do not apply. 
4.1  Knowledge, Attitudes and Behaviour of Community citizens 
The most important and  fundamental  consideration  in  the attainment of Community  self-
sufficiency is the willingness of the citizens of the Member States to donate the blood and 
plasma required both for direct transfusion and for the preparation of  medicinal products. And 
their perceptions, realistic or not, play a crucial  role. 
As set out in its Communication on blood self-sufficiency, the Commission has now carried 
out a survey of the knowledge, attitudes and behaviour of the general public regarding blood 
and  blood  donations  within  the  framework  of the  EUROBAROMETER  public  opinion 
surveys.  In  April  1994,  approx.  13,000  European  citizens  of the  15+  age  group  were 
interviewed  on a  nationally  representative  basis  in  all  12  Member  States  regarding  their 
perception and understanding of questions relating to blood. 
The major findings showed that Community citizens are reasonably well-informed about blood 
and are aware of the existence of different blood groups. There is, however, general lack of 
awareness about the frequency with which blood can be donated, what plasma is and the fact 
that  it  Can  be donated  instead  of whole blood.  Health  problems or negative  advice from 
doctors, lack of  time, and fear of  getting AIDS were the major reasons given for not donating 
blood. And in spite of general awareness that blood donations are tested for diseases, a large 
percentage of  Europeans are afraid of  having a blood transfusion, primarily because of  the fear 
of contracting  HIV/AIDS.  Moreover,  there  is  a  general  lack  of awareness  about  the 
Community's  goal  of self-sufficiency  through  voluntary  non-remunerated  donations  even 
though this goal is generally supported. 
Based on the number of misconceptions that exist among European citizens regarding blood-
related issues, there is a need to continue to ascertain people's knowledge about this important 
subject, in particular so that they can be provided with factual and reliable information. 
4.2  Voluntary non-remunerated donations 
Non-remunerated blood donation  is one of many health care issues that are the subject of 
divergent views today. While regulations concerning donor recruitment have been established 
by some Member States, differences of opinion about the ethical principles and safety issues 
related  to  "incentives"  or  "compensations"  given  to  blood  and  plasma  donors  persist. 
Furthermore,  the definition  of voluntary  non-remunerated  donation  as  put forward  by  the 9 
Council of  Europe
24 is viewed differently by the Member States particularly as it relates to the 
relevant provision in Directive 89/381/EEC. 
4.2.1  Regulations 
A survey carried out by the Commission shows that regulations and practices related to donor 
recruitment and voluntary non-remunerated donations in the Member States vary widely  from 
explicit legislation, to general health regulations but with no precise reference to remuneration, 
to no specific stipulations. A few Member States stated that in their legislation non-compliance 
with the principle of voluntary non-remunerated donations could result in  legal action. 
In the Member States, donors are generally voluntary and under no pressure to donate. Some 
strictly prohibit directed donations by family or friends or where the donor and recipient know 
each other. In situations where blood shortages exist, however, friends and family members 
of patients in a few Member States may  be asked to donate.  In those that are not yet self-
-sufficient, physicians may make treatment conditional on the availability of  blood, which could 
put pressure on the patient as well as on his/her relatives to donate. In some Member States, 
regular donors are contacted by  telephone or letter by  the transfusion services or by  donor 
organizations. 
It is not the practice in the Member States to collect blood in  prisons and  one specifically 
reported that it is not carried out in refugee centres. Some countries collect from  soldiers in 
civil and military centres, others do not. 
4.2.2 .  Practices 
The incentives provided to both blood and plasma donors within the Member States range 
from absolutely no payment or reimbursement, to days off work, or to "expense allowances". 
Donors normally receive refreshments (a non-alcoholic drink and biscuits or sandwiches) in 
order to replace fluid loss and as a way of ensuring that they rest after the donation to reduce 
the risk of fainting.  In all  Member States,  their generosity is generally recognized through 
medals, certificates, diplomas and small gifts of negligible commercial value, commensurate 
with the number of donations, as well as official award ceremonies and celebration parties for 
high frequency donors. 
One Member State provides free medical care to donors when proposed  by the blood services 
and provides its voluntary blood donor groups with meeting and record storage facilities, as 
well as financing for its promotional leaflets and telephone expenses. 
Member  States  permit time  off work  for  donations  ranging  from  the  net  time to donate 
blood/plasma  to  one  day  off work  which  in  one  country  is  specifically  restricted  to  a 
maximum of four days per year for blood and plasmapheresis donations.  A voucher 11ystem 
for plasmapheresis (voucher ±  1.25 ECU) is in place in one Member State. 
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A donation is considered voluntary and non-remunerated if  the person gives blood, plasma or 
cellular components on his/her own free will and receives no payment for it, either In the form of 
cash, or in kind which could be considered as substitute for money.  This would include time off 
work other than that reasonably needed for the donation and travel. Small tokens, refreshments 
and reimbursements of direct  travel  costs  are  compatible  with  voluntary,  non-remunerated 
donations. (Council of  Euro~) 10 
Reimbursement of travel  expenses ranges from  none at all,  not even upon presentation of a 
bus or train ticket,  to actual  travel  costs when  requested,  particularly when the donor has to 
travel a long distance or at night.  In one Member State, transportation, if  required, is provided 
by  blood  banks  and  in  a  few  cases  (plasmapheresis  combined  with  long  journeys), 
reimbursement is given, when supported by documentation,  to the employer for the time off 
work 
Blood and plasma representatives, in one Member State, have adopted a recommendation that 
while no  payment should be  made for the  donation  of blood  or plasma itself,  an  "expense 
allowance"  of up to a maximum of 25  ECU per donation is justifiable and compatible with 
the guidelines of the WHO and the Council of  Europe.  These representatives have espoused, 
however, that no "expense allowance" should be paid for the first donation and an upper limit 
must be imposed  in the case of frequent  plasma donations so that the  "expense allowance" 
cannot  be assimilated  to  a payment.  In  this  country,  both  state and  local  authority  blood-
donation  services  as  well  as  commercial  plasmapheresis  centres  provide  donors  with  an 
"expense allowance" for direct costs (e.g.  for the journey and time taken),  which  is granted 
as a lump sum  in order to avoid administrative costs.  Whole-blood collections organised by 
the Red Cross in the same Member State, however, are without any such "expense allowance". 
From the foregoing, it is evident that the interpretation of the concept of non-remuneration is 
not uniform throughout the Community. Incentives to encourage blood and plasma donations 
do take place including time off work beyond that actually required for the donation and flat 
rate "expense allowances". 
4.3  Optimal Use 
Optimal  use of blood and  blood  products without depriving patients of what they need  can 
contribute to achieving Community  self-sufficiency.  Yet it is  known  that practices differ in 
the Community. A study, known as SANGUIS (Safe ANd Good Use of blood In Surgery)
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was  carried out between January  1990 and  June  1992 within the framework of a European 
Community  Research  Concerted  Action  to  assess  when,  why  and  how  much  blood,  blood 
components,  plasma  derivatives,  and  artificial  colloids  were  requested  and  transfused  in 
specified elective surgical procedures carried out in university hospitals in Europe.  This study 
showed that in a large number of teaching hospitals in the Community, utilization of specific 
products varied widely between hospitals in the same country and more so between hospitals 
of central-northern Europe and the Mediterranean countries.  The use of whole blood in some 
hospitals was found to be quite high and in others where whole blood was not requested, red 
cells and plasma were often used together, effectively reconstituting whole blood and negating 
the widely accepted concept of  blood component therapy. In some hospitals, plasma was used 
for volume replacement, thereby removing plasma from fractionation and effectively negating 
efforts elsewhere towards self-sufficiency. 
One of the main conclusions of this study was the profound and totally unexplained variations 
in the use of blood products in six surgical procedures for similar categories of patients and 
showed inter alia the need for improved  use of blood resources through agreement on  best 
blood transfusion practice. 
25  Safe and good use of blood in surgery (SANGUIS)  - Use of blood products and artificial 
colloids in 43  European hospitals. EUR  15398.  G.  Sirchia et al  (eds). European Commission. 
1994. 23Sp.] 11 
4.4  Progress towards Community selr-sufficiency in  1991 
Periodic updates regarding blood and plasma donations and the availability and use of blood 
products in the Community, as suggested in the Communication on blood self-sufficiency and 
endorsed by the Council on 13  December 1993, can provide an indication as to the progress 
that is being made towards Community self-sufficiency. The survey of the situation in  1991
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showed inter alia that from  1989 to 1991 : 
Whole blood donations increased in ten of the twelve Member States. 
Member  States  were  almost  entirely  self-sufficient  for  whole  blood  and  blood 
components  in  1991,  except  Greece  which  requires  large  quantities  of red  cell 
concentrates for its thalassaemia patients. 
The volume of plasma obtained from  voluntary,  non-remunerated whole blood and 
plasmapheresis donations increased by 20%. 
The volume of plasma available for fractionation, derived both from whole blood and 
obtained through apheresis from voluntary, non-remunerated donors, increased by 36%. 
The degree of plasma self-sufficiency improved significantly despite increased use of 
certain plasma products notably factor VIII concentrates. 
Use of fresh  frozen  plasma  and  whole  blood  for  transfusion  decreased  reflecting 
progress towards optimal use of blood and its components. 
Large differences still exist a.-:1ong the Member States regarding use of fresh  frozen 
plasma, factor-vm concentrates, and albumin. 
The  plasma  shortage  for  preparing  medicinal  products  persisted  necessitating 
importation of both plasma and final  products from  outside the Community mainly 
from the USA. The amount of plasma imported, primarily by the Federal Republic of 
Germany, Italy and Spain, increased by 5%.  The amount of factor-VIII concentrates 
imported, primarily by the Federal Republic of Germany, increased by 16%. 
Information about the  situation  regarding blood and  plasma collection  and  use  in  1993  is 
currently being compiled and a revised questionnaire for use in  1995 has been finalized. 
4.5  Trade in blood and blood products 
Irrespective of the method of collection, considerable expense is incurred in the collection, 
testing, processing, storage, distribution and use of  blood and blood products as well as related 
research and development.  These activities must be financed either through the health care 
system or through normal market procedures. 
26  The CoUection and Use of  Human Blood and Plasma in the European Community in 1991. W.G. 
van Aken. July  1994. European Conunission.  CEC/LUXN/F/159194. 39p. 12 
:\s  most  Member  States  have  achieved  self-sufficiency  in  whole  blood  and  cellular 
components, exchanges between Member States are limited. Exchanges of fresh components 
do occur but usually when shortages exist. Member States that have an excess of red blood 
cells do make them available at cost to third countries and one Member State that experiences 
a shortage of  this blood component on a continuing basis currently obtains it from outside the 
Community. 
The situation with regard to source plasma used in the preparation of medicinal products and 
the  products  themselves  is  quite  different.  Currently,  there  is  a  deficit  throughout  the 
Community in the quantity of plasma derived from voluntary non-remunerated donations to 
enable both the public and private sectors of  the plasma products industry to produce sufficient 
medicinal products to satisfy existing demand. As a result, much of the source material, i.e. 
plasmapheresis plasma,  used for fractionation  by the private sector,  is obtained from  paid 
donors fro~  third countries, in particular the United States where there are no laws prohibiting 
payment; and.donors may receive USD10-15 for each donation of  about 650 ml and may give 
up to 60 litres per year. 
In  addition,  final  products,  such  as  factor  VIII,  albumin  and  immunoglobulins,  are  also 
imported.  Curtaili.ng such imports (both plasma and final  products) at this time would have 
adverse consequences especially for hospital patients, those requiring emergency care, as well 
as  those suffering from blood disorders such as haemophilia.  · 
Euroslat data indicate that in the past trade in source plasma and plasma products between the 
Community and third countries has  been  conducted  primarily with  the  USA and  Austria. 
Importations from the United States are significantly higher than exportations to it due in part 
to  the  licensing  and  inspection  requirements  imposed  by  the  US  Food  and  Drug 
Administration. Exports from the Community in the past have been primarily to Austria. 
Within the Community,  manufacturing and marketing of medicinal  products  derived  from 
blood  and  plasma  is open  to both  the  public  and  private  sectors of the  plasma  products 
industry provided all marketing conditions are met. While it is estimated that the market share 
is  currently  divided  between the  public  (400/o)  and  private  (600/o)  sectors,  with  the latter 
providing between 60-1000/o for particular products, the private sector considers that measures 
introduced in the name of  national self-sufficiency on the basis of  non-remunerated donations 
in  some Member States deprives it of the opportunity  of marketing  its products  in  those 
Member States.  It is also of the view that these regulations which impede the placing on the 
market of  medicinal products derived from paid plasma create a monopolistic environment that 
could lead to increased costs for medicinal  products and deprive patients and physicians of 
continued access to new technologies and products. This point of view is countered by several 
Member States that have established publicly-run systems which,  in their opinion,  address 
these concerns. Some Member States require ~fication  that blood products are derived from 
voluntary unpaid blood donors. 
Development  of genetically  engineered  plasma  derivatives  and  alternatives  to  cellular 
concentrates (i.e.  soluble haemoglobin) may have significant consequences in  the future on 
blood donations, the usage of products, the pricing of medicinal products derived from blood, 
as well as on the exchange of these products. 13 
5.  BLOOD SAFETY AND CONDmONS FOR ITS AITAINMENT 
While significant advances have been made towards making blood and blood products safe, 
it must always be borne in mind that the biological nature of blood and plasma makes them 
susceptible to contamination and since new infectious complications cannot be excluded, the 
task  of minimizing the  risks  associated  with  blood transfusion  is far  from  complete.  New 
technologies that continue to emerge will  require close scrutiny for their ability  to improve 
on current standards of screening for infectious diseases. 
5.1  Collection  p~ocess 
Safety  of blood  and  plasma collection  involves  two  main  activities  - selection  and  testing. 
Selection  refers  to  the  clinical  processes  of enquiry  involving  some  form  of interaction 
between  a  blood  transfusion  service  professional  and  the  donor,  based  on  a  structured 
questionnaire  and  supported  by  additional  detailed  guidance  documents.  Testing  is  the 
laboratory examination of a sample of  the donation to determine specific biological parameters 
and  to  detect.  through  so-called  infectious  markers,  the  presence  of agents  that  produce 
communicable diseases. 
5.1.1  Selection of donon 
With  the  number and  kind  of infectious  markers  differing  from  Member  State to Member 
State,  and from  region to region within  a Member  State,· as well  as a higher probability  of 
these occuring in first time donors, donor selection is of vital importance. The donor selection 
process, however, differs across the Community. Whether the donation is for whole blood or 
plasmapheresis plasma, variations exist: 
in the frequency  of the clinical examination,  ranging from  a medical examination at 
every donation to none routinely required; 
in the person who conducts the donor interview who varies from a physician to a trai-
ned staff member of the collection centre; and 
in the information programmes for both donors and the general  public. 
The process,  however,  generally includes the administration of a questionnaire which again 
differs both within and across Member States. 
The reliability and effectiveness of  questionnaires in eliciting information about potential risk 
factors or exposure to diseases,  such as mv, both from first time donors and those donating 
repeatedly has yet to be determined. This is significant when it is realized that the incidence 
of infectious markers is 5-20 times higher in first  time donors.  It should also be noted that 
many  repeating donors may  sign a donor declaration without carefully re-reading  it.  Donor 
selection, therefore, is a crucial link in the safety of the blood transfusion chain. 
In view of the increased mobility of persons within the Community and the potential for the 
introduction of more obstacles to the  movement of blood  and blood  products,  it would  be 
beneficial if  an agreement is reached as  regards the rules and practices for donor selection, 
including n~  and repeat donors as well  as donors of whole blood, cellular components and 
plasma, to be applied across the Community.  · 14 
5.1.2  Testing of donations 
Directive  89/381/EEC  and  the  accompanying  provisions  were  aimed  at  hannonizing  the 
quality,  safety,  and  efficacy  requirements for medicinal  products derived from  blood,  thus 
ensuring their free circulation. Article 3.1 of  the Directive requires that testing of  human blood 
and  plasma,  when used as the starting material  for the manufacture of medicinal  products, 
shall comprise those measures recommended by the Council of  Europe and the World Health 
Organization  (WHO)  as  well  as  the  application  of the  monographs  of the  European 
Phannacopoeia regarding blood  and  plasma.  The provisions of the latter have  been made 
applicable by Directive 91/507/EEC and are supported by guidelines developed by the CPMP. 
As these Directives do not apply to whole blood, to plasma or to blood cells of human origin, 
divergences exist within the Community  regarding the testing  requirements  for blood and 
plasma donations. 
Some Member States do not differentiate at the collection stage between blood for transfusion 
and  blood that is destined  or may  be used  for fractionation;  others do.  As a consequence, 
testing requirements that may be compulsory in one Member State for blood and plasma for 
fractionation may not be in another. This can result in medicinal products derived from plasma 
manufactured in accordance with the regulations of one Member State being prevented from 
appearing on the market of another because a particular test has not been carried out. As an 
example,  one  Member  State  requires  each  donation  to  be  screened  for  syphilis  with  the 
consequence that no product is allowed to be placed on its market, even coming from another 
Member State, that does not have a similar requirement. 
Both the public and private sectors share the concern that these differing testing requirements 
in Member States throughout the blood transfusion chain are introducing barriers to trade of 
medicinal  products derived from  blood. 
The scientific -basis for some differences in testing requirements between blood for transfusion 
and for fractionation is clear. For example, HTL  V-I and II appear only in the cellular fraction 
and are thus removed in the first manufacturing stage of  the medicinal products derived from 
blood or plasma; the syphilis agent is rapidly inactivated by freezing the plasma, a process to 
which all  collected plasma is subjected.  A particular point of contention among the Member 
States  is  alanine  aminotransferase  (AL  T)  testing  which  was  originally  introduced  as  a 
surrogate test for post-transfusion hepatitis when specific screening for hepatitis C was not yet 
possible.  This  test  is  not  included  in  the  list  of  mandatory  tests  of  the  European 
Phannacopoeia monograph on plasma for fractionation.  As this monograph is worded so as 
to allow flexibility, however, some Member States require this test while others do not. 
It is  evident that the  differing  testing  requirements  in  the Member  States hinder the free 
movement  of ·blood  and  blood  products  and  are  therefore  an  impediment to the goal  of 
Community self-sufficiency. 
5.2  Regulatory Controls 
In  each  Member  State,  there are  responsible  bodies  for authorizing the manufacturing of 
pharmaceutical products and the monitorin~ of procedures in order to ensure that higp levels 
of quality  and  safety  are maintained.  Inspectors are  required to make on-site visits to the 
manufacturer to  ensure  regulations  are  being followed  and  negative  reports  can  result  in 
closure until corrective measures are taken. In accordance with Community legislation,  each 
Member State is  responsible for inspections on its own territory, and information exchanges 15 
between the competent authorities, such as through the CPMP,  help to facilitate the resolution 
of problems between them. 
In at least one Member State, blood is considered a medicinal product and is therefore subject 
to pharmaceutical regulation. This is not the case, however, in others. On the basis of an on-
going survey being carried out by the Commission, there are preliminary indications that the 
regulatory controls regarding licencing. and accreditation of blood collection establishments 
differ  widely  across  the  Member  States.  Many  have  no  licencing  requirements  for  the 
collection of blood or plasma;  no  standard  requirements  for  collection  centres  across  the 
country;  no  routine  and/or  unannounced  inspections  by  national  authorities  nor  peer 
inspections,  and  differing  time  periods  for  licence  renewals.  In  one  Member  State,  the 
extraction of blood and blood components for transfusion as well as the extraction of plasma 
for  fractionation constitutes the manufacture of medicinal  products, for  which  a licence is 
required.  In others, this interpretation does not apply. 
This existence of divergent national  regulations concerning the collection and  treatment of 
blood contributes to a reluctance, if not a refusal, on  the part of certain Member States to 
accept blood and plasma coming from  others.  Serious consideration, therefore,  needs to be 
given  to  harmonizing the licensing  and  accreditation  of blood  collection,  processing  and 
distribution establishments across the Community that do not fall within the scope of  Directive 
89/381/EEC. 
6.  THE NECESSITY FOR FUTURE COMMUNITY ACTION 
6.1  Increased awareness 
As a result of the AIDS pandemic as well  as  several  incidents related to the distribution of 
cor;ttaminated  medicinal products derived from blood and plasma in the Community, public 
confidence  in  the  blood  transfusion  system  has  been  seriously  undermined.  Patients  and 
persons with haemophilia have been particularly affected. Demands for stricter regulations of 
the blood transfusion system have increased. It is extremely important that the confidence of 
the citizens of the Community is  reestablished~ this can be done by means of a number of 
measures including  appropriate information and education campaigns. 
The results of the Eurobarometer survey show that knowledge about blood-related issues in 
the Community is inadequate and is insufficient in  relation  to the goal of Community self-
sufficiency. There is the need, therefore, to increase awareness levels among the population 
regarding blood and plasma, its uses,  the precautions that are taken to maximize safety,  as 
well  as the goal of Community self-sufficiency. This could be done through better targetted 
campaigns of a general nature or specifically targetted to blood awareness.  There is also the 
need to have more detailed information about the knowledge and attitudes of specific groups, 
such as students,  regarding blood and blood donation with the view to enlarging the blood 
donor base. The latter could be done in cooperation with blood donor groups. 
6.2  Donor selection criteria 
The  process  of donor  selection  should  be  properly  monitored  and  documented  and  its 
effectiveness should be demonstrated properly in particular by reference to an acceptable low 
level of frequency of infectious markers.  In spite of the fact that several guidelines, including 
those of the Council  of Europe, already  exist in  this  area and  certain Member States have 16 
relevant  requirements  embodied  in  regulations,  there  is  significant  variation  in  the  donor 
selection processes in the Member States. There is the need  for common procedures among 
blood and plasma collection centres within the Community if obstacles to the movement of 
these  products are to be overcome.  These common  procedures would  help  to  provide the 
necessary reassurances of the safety of blood and blood products originating from  whatever 
Community source. 
A  first  step  in  this  process  could  be taken  by  the  development  of a  common  and  well-
structured  questionnaire  with  appropriate  criteria  for  the  selection  of donors  taking  into 
account the differing social/cultural environments in the Community and the regulations and 
procedures currently  in force.  An  examination of the  efficacy  of existing donor  selection 
procedures ci:>uld  provide a basis on which to select the criteria for such a questionnaire so 
as to provide optimal guarantees for the safety of the donor and the recipient. 
6.3  Testing of donations 
Despite the existence of testing requirements in the Community, some differences remain in 
the screening of blood and plasma for transfusion and for fractionation in the Member States. 
As  the importance of these screening tests cannot be overestimated, the available scientific 
data, both in favour and against specific screening testS1  need to be compiled so that a .sound 
basis against which to establish  their validity  tan be  developed.  There is  a clear need  for 
harmonization in this respect to ensure the free circulation of medicinal products derived from 
blood  but also to facilitate  the future  centralized procedure for  authorization of medicinal 
products.  Moreover, a comparative survey is needed of the currently used testing kits in the 
blood transfusion field, their proficiency and proper utilization, as well as the licensing of  the 
critical  diagnostics intrinsic to ensuring the safety of the  blood supply  :me  quality  control 
measures in the Member States. 
6.4  Optimal use 
Attitudes towards blood transfusion and the use of medicinal products derived from  plasma 
have changed in the last ten to fifteen  years due to the emergence of blood-borne diseases 
(notably IDV), new medical technology, increasing health care costs, and the results of  clinical 
trials. Knowledge about the clinical effectiveness of  the varying approaches to the prescribing 
and  use  of blood  and  blood  products  across the Community,  however,  is  hampered  by  a 
continuing  lack  of access  to  and  provision  of relevant  information  thus  inhibiting  the 
establishment of policies regarding their optimal use.  Both the self-sufficiency surveys and 
the SANGUIS study have demonstrated wide variations in transfusion practices in the Member 
States.  Consensus conferences and guidelines on the use of specific blood products do not 
appear to have had a significant impact on changing the behaviour of physicians and there is 
a  need,  therefore,  to  carry  out  studies  on  the  optimal  use  of blood  and  blood  products 
recognizing that its significance is directed towards: the patient - whose safety and therapy are 
of paramount importance; the donor - who should be guaranteed that his/her donation is used 
in the best possible way; self-sufficiency - ensuring that source materials (blood and plasma) 
are used optimally;  good clinical practice- ensuring inter alia that blood and blood products 
are administered only when needed; and finally the financial  implications.  Moreover, there 
is a need to include in a standardized way in clinical records the reasons for transfusion, its 
actual  administration and the outcome. Results of further  studies could be used as the basis 
for establishing sound blood transfusion practices throughout the Community. 17 
6.5  Regulatory system 
With  the increasing  movement  among Member  States  of blood  products  and  blood  units, 
which  are being drawn  in  one  country  for  transfusion  in  another,  differing  licensing  and 
inspection  requirements  for  both  blood  and  plasma  collection  establishments  across  the 
Community stand in the way of the free movement of blood and blood products and thus the 
objective of  Community self-sufficiency. Common requirements including quality control and 
quality assurance procedures and good manufacturing practice, which have been established 
for medicinal products derived from blood and plasma, need to be defined and agreed upon 
for blood collection establishments and inspection and certification programmes need to be 
put in place.  The objectives of such programmes would be to verify the implementation of 
requirements agreed upon and to provide a tool for the improvement of  practices as they relate 
to  donors and patients.  Such an  inspection and  certification  programme would  have to be 
determined in consultation with the responsible authorities of the Member States. 
6.6  Haemovigilance 
The  minimization  of risks  associated  with  blood  transfusion  constitute  a  major  priority. 
Because blood transfusion deals with a biological material in which infectious agents may be 
present, it is essential to be ever vigilant so that potential biological changes can be detected 
at  any  time.  Moreover,  since  there  is  insufficient  information  as  to  the  precise  extent of 
infection  or  transfusion  errors,  there  is  the  need  to  develop  concrete  measures  for  their 
prevention. This applies also to the immune reactions that may follow a transfusion as a result 
of previous immunizations (e.g.  pregnancy, previous transfusion). 
As  indicated  in  the  Commission's  Communication  related  to  AIDS  and  certain  other 
communicable diseases,  there is . a need  to improve,  at  Community level,  the  availability, 
quality, relevance and dissemination of  data related to diseases transmitted by inter alia blood. 
Establishment of Community-wide surveillance systems on blood transmitted  diseases and 
adverse  reactions  at  both  national  and  Community  level  could  help  to  keep  transfusion 
specialists informed, in a timely and orderly fashion,  of new infectious agents in  particular, 
their potential danger, and appropriate measures to be taken to avoid their transmission.  Such 
a system  could be based on  a network of blood transfusion centres linked with national  or 
Community epidemiological agencies which are looking at these issues on a broader scale. 
Existing  haemovigilance  and  pharmacovigilance  systems,  therefore,  would  need  to  be 
examined in  order to assess their contribution to such a system. 
6.7  Continuing close cooperation with Member States 
The Communication on blood self-sufficiency in  the European Community was based inter 
alia on  the  results  of a joint enquiry  conducted for  the Commission  and  the  Council  of 
Europe
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, took into account the comments received from representatives of  the Member States, 
and identified issues and priorities for action. This Communication on blood safety and self-
sufficiency has taken into account information provided by the Member States in these areas 
as well as issues of ~ncem  and activities to be undertaken expressed by the Member States 
at meetings held by the Commission. 
27  Collection and use of human blood and plasma in Europe.  W.G.  van Aken. Council of Europe. 
1993.  3lp. (ISBN 92-871·2240·7) 18 
In  view of the complexity of the issues rdated to blood transfusion as well as the importance 
of blood and blood products to the health of the citizens of the Community, the Commission 
will  continue to draw upon the expertise of  representatives from  the Member States.  Their 
medical,  scientific,  manufacturing and  managerial  expertise in  relation  to  the  operation  of 
blood transfusion services, will continue to be of assistance to the Commission in addressing 
issues related to blood safety and self-sufficiency in  the Community. 
7.  BLOOD SAFETY AND  SELF-SUFFICIENCY:  THE NEXT STEPS 
In  cortelusion,  there is  a  clear  need  to  formulate  a  Community  blood  strategy  aiming  at 
improving  confidence  in  the  safety  of the  blood  transfusion  chain  and  promoting  self-
sufficiency in the Community. 
To this end,  the main activities to be undertaken could include: 
Development  of scientifically  sound  policies  and  agreed  procedures  in  the  donor  · 
selection  process among  blood  collection  establishments  within  the  Community  in 
order to provide the necessary reassurances of the safety of blood products originating 
from  whatever Community source. 
Implementation of efficient validated and reliable screening tests in  the Community. 
Development  of  quality  assessment  criteria  and  good  manufacturing  practices 
regarding collection, testing, processing, and transfusion of blood and blood products 
and patient follow-up procedures. 
Development of a haemovigilance system  for the collection of epidemiological data 
related to the blood transfusion chain. 
Development of  educational programmes directed towards health professionals on the 
optimal use of blood and blood products. 
Support for the dissemination of infonnation on  blood  and blood  products and  the 
collection, processing and transfusion procedures through promotional materials, films, 
campaigns. 
The Commission will  continue to collaborate with the Member States to develop this  blood 
strategy and will  report on the progress made in this regard in due course. 19 
ANNEX I 
Therapeutic Uses  of Blood Products 
Blood Products  Therapeutic Use 
CELLULAR COMPONENTS aad PLASMA 
Red blood cell coaceatrata 
Platelet coaceatntel 
Fresh frozea pluma (FFP) 
PLASMA DERIVATIVES 
Albumhr 
Clottiag factor coaceatntes 
Pro&eue lablblton 
lmmuao&lobullu 
RBCs are administered when the oxygen canying capability of 
blood is ctiminisbed  so  that organs or tissues  no  longer function 
properly primarily  as a consequence of blood loss due to  trauma 
(e.g. car accidents), surgery, or delivery, or loss of red cells because 
of hereditary diseases such as thalassemia. 
Patients  sufJeri,ng  from  platelet  deficiencies,  particularly  those 
undergoing  treatment  for  blood  disorders  (e.g.  leukaemia),  and 
cancer patients  receiving  chemotherapy  and  irradiation,  receive 
platelet concentrates to prevent life-threatening bleeding. 
Plasma which after collection is  frozen to a temperature that will 
maintaia the activity of labile coagulation factors is called FFP. It 
is used to treat bleeding in patients undergoing liver transplantation 
and  for  some  rare  clotting  factor  deficiencies.  It is  also  used 
postoperatively and inadvertently as a nutritional substitute. 
Albumin is used primarily when loss of blood or severe infection 
(septicemia) causes a drop in blood pressure giving rise  to  shock. 
Albumincficiency,  caused  by  its  decreased  synthesis  (e.g.  in 
patients with severe liver disease) or losses (e.g. severe burns) may 
also be an indication for its administration. 
These are used principally to treat bleeding episodes in patients with 
shortages in one or more of  these proteins (e.g. haemophilia A); and 
regular injections improve both their quality of life (e.g.  less joint 
iqjury) and longevity. 
Protease inhibitors (e.g. antithrombin III) cwb excess clotting factor 
activity. Deficiency of these proteins may  cause diseases such as 
veDOUS  thrombosis  and  lung  emphysema  which  arc  prevented 
through treatment with protease inhibitor concentrates. 
1bcse arc plasma proteins that play a role in the defense mechanism 
against viral and bacterial infections. They arc used mainly  in the 
prevention of a variety  of infectious  diseases  such as  hepatitis, 
smallpox, chicken pox, tetanus, and rabies and in the treatment and 
prevention  of haemolytic  disease  of the  newborn  due  to  Rh 
iDCOmpatibility.  Increasingly  high doses of immunoglobulins  arc 
being used to treat patients with auto-immune diseases and further 
indications for their use arc increasing. 20 
ANNEX 2 
Major Infectious Agents Transmissible by Blood and Blood Products 
INFECTIOUS AGENT 
Viruses* 
Human immunodeficiency virus type 1 (HIV  -1)  } 
Human immunodeficiency virus type 2 (HIV-2) 
Human T-cellleukaemia virus type I  (HTLV-1)  } 
Human T-cellleukaemia virus type II (HTLV-11) 
Hepatitis A virus (HA  V) 
Hepatitis B virus (HBV)} 
Hepatitis C virus (HCV) 
Cytomegalovirus (CMV) 
Epstein-Barr virus 
Parvovirus B 19* 
Spirochetes** 
Treponema pallidum 
Borrelia burgdoferi 
Parasites**  (rare in the Community) 
Plasmodium species 
Bacteria 
Contamination with a variety of bacteria 
can occur at the time of donation. 
OUTCOME 
AIDS 
myelopathy 
acute T  -cell  leukaemia 
acute hepatitis 
acute/chronic hepatitis 
liver cirrhosis 
liver cancer 
pneumonitis 
glandular fever 
aplastic crisis 
foetal  loss 
syphilis 
Iyme disease 
(barrel i  osi s) 
malaria 
septicaemia 
*  Are  not  transmitted  by  virally  inactivated  plasma,  with  the  exception  of 
parvovirus Bl9 
**  Transmitted only by the cellular components 21 
21 
ANNEX 3 
Eurobarometer Survey 
European citizens  are reasonably well-informed about blood:  98% are aware of the 
existence  of different  blood  groups;  9()0A,  are  aware  that  donating  blood  does  not 
pennanently reduce its volume in the body; and  89"A.  are aware that blood donations 
are tested for diseases.  Television  is the dominant information source. 
There  is  a general  lack of awareness  about the  frequency  with  which  blood  can  be 
donated. 
Knowledge  about  plasma  is  lacking  with  only  34%  aware  that  it can  be  donated 
instead of whole blood with this most apparent in Greece (14%), Portugal (18%) and 
Denmark (18%)
21
. 
Donating blood is considered by about half those interviewed as the right thing to do. 
Interviewees would donate to support a relative or friend  (33%), in case of a major 
disaster (30%), before an operation (26%), and because of  the rarity of  the blood group 
(25%). 
There are significant variations in the acceptance of blood donated by anyone: overall 
(46%),  Denmark  (80%),  U.K.  (73%),  The  Netherlands  (70%),  Italy  (33%)  and 
Germany (24%). 
The general  opinion (78%) is that freely  donated  blood should be  provided free  of 
charge to  people who  need  it;  a charge to cover collection,  testing and  distribution 
costs  would  be  acceptable to  13%; a charge over and  above  these  costs  to  finance 
research, information and donor campaigns is supported by 6%. 
Only  1% approved of selling blood as any  other product while 55% considered that 
blood should be given for the sake of giving. 
Over  half (55%) believe that blood transfusions  are  safer today  than  they  were  10 
years ago,  14% believe they are as safe,  while 23% doubt their current safety. 
Because of AIDS, 70% are more afraid than before regarding the safety of blood and 
blood products. Giving blood is frightening for 27%, with this response much higher 
in Portugal (51%) and Spain (  41%  ). 
Receiving blood  is of  concern to a large percentage of  Europeans (73%), particularly 
in  Italy  (87%);  having  an  injection (35%) and  having  an  operation  (47%) is  more 
frightening now than about 10 years ago. 
Note:  Denmark has been self-sufficient in plasma derived from whole blood for several years. 22 
ANNEX 4 
Major Survey Findings on Self-sufficiency in  1991"
19 
From  1989 to  1991: 
29 
30 
The number of whole blood donations increased by about 6% from  15.2 million
30  to 
16.1  million. 
Use of red blood cell concentrates (RBC) remained unchanged (data from  Germany  not 
included); the number of whole blood transfusions declined by 7%; use of fresh frozen 
plasma dropped by 200/o;  and consumption of platelet concentrates increased by 32%. 
More than 4.1 million litres of plasma were collected from whole blood donations and 
plasmapheresis from  voluntary, non-remunerated donors - a 20% increase. 
The vo!ume of plasma derived from whole blood available for fractionation increased 
by  47% from  1. 7 to 2.5  million litres;  the volume obtained through apheresis from 
voluntary, non-remunerated donors increased by 22%. The total volume of plasma for 
fractionation increased by 36% - from  2.5  to 3.4 million litres. 
Importation of plasma for fractionation from outside the EC, primarily by the Federal 
Republic of Germany, Italy and Spain, increased by 5% from 2.0 to 2.1  million litres. 
Total consumption of factor-VIII preparations was 827.8 million IU- an 11% increase 
(As  1989 data for Germany was unavailable, it was not included in calculation). The mean usage 
per patient ranged  from  0.4  (Greece)  to  4.7  (Luxembourg)  with  varying treatment 
regimens accounting for the differences.  Total consumption of albumin preparations 
amounted to 82,328 kg,  an increase of 5%. 
The plasma volume required .  to satisfy the reported use for factor-VIII concentrates 
varies between 4.6 and 5.5 million litres depending on the final yield. Considering the 
3.4 million litres available for fractionation, the resulting plasma shortage was 1.2 to 
2.1  million litres. 
The quantity of factor-VIII concentrates imported (mainly from  the USA), increased 
by  16% to 273  million units (primarily by  Germany). 
Use of factor  VIll products  increased  by  11%  while  the  number  of haemophilia 
patients treated regularly increased by  3%. 
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